A novel outpatient intervention might provide a solution for the substantial proportion, estimated at 70%, of individuals who discontinue popular weight-management therapeutics and subsequently experience weight regain. This prospect is highlighted by research slated for presentation at Digestive Disease Week® (DDW) 2026. A significant segment of the adult population grappling with obesity, close to one in five, has utilized glucagon-like peptide-1 (GLP-1) agents. However, a prevalent issue arises when patients cease these medications, often leading to the reversal of their weight loss within an average timeframe of 18 months.
The current study introduces the inaugural blinded, randomized, and sham-controlled findings demonstrating that a procedure identified as duodenal mucosal resurfacing holds promise as a secure, efficacious, and enduring method for sustaining drug-free weight loss subsequent to the cessation of GLP-1 therapy.
While GLP-1 medications exhibit considerable effectiveness, a multitude of patients discontinue their use due to prohibitive costs, adverse effects, or a general aversion to long-term pharmaceutical intervention. Nevertheless, upon discontinuation of these agents, the overwhelming majority of patients experience a recurrence of lost weight, along with a forfeiture of the associated metabolic advantages. The identification of a therapeutic modality that empowers patients to halt these medications without succumbing to weight rebound or compromising metabolic benefits represents a significant unmet clinical need. The outcomes of this research suggest that this minimally invasive procedural approach may facilitate sustained weight management.
Shelby Sullivan, MD, lead author, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center and professor of medicine, Dartmouth Geisel School of Medicine
Duodenal mucosal resurfacing is currently an investigational endoscopic technique that employs targeted thermal energy to ablate—or thermally destroy—the aberrant inner mucosal lining of the duodenum. This segment constitutes the proximal portion of the small intestine, situated directly inferior to the stomach. The REMAIN-1 trial is actively investigating whether duodenal mucosal resurfacing, by promoting the regeneration of healthy tissue, can lead to a durable metabolic recalibration.
These findings are derived from the initial cohort of participants in the trial, who have now completed six months of post-intervention follow-up. Within this midpoint cohort comprising 45 individuals, 29 underwent the resurfacing procedure, while 16 received a sham intervention. All participants had previously achieved a minimum of 15% total body weight loss through the administration of tirzepatide before discontinuing the medication.
On average, participants had shed approximately 40 pounds while undergoing GLP-1 therapy. At the six-month mark following the cessation of the drug, individuals who received the sham procedure exhibited a 40% greater incidence of weight regain compared to the actively treated group. Furthermore, those who underwent more extensive mucosal resurfacing regained a mere 7 pounds, thereby retaining over 80% of their initial weight loss. In contrast, the sham control group experienced a weight regain approximately twice that amount. The disparity observed between the treatment and control cohorts appears to be progressively increasing from the one-month to the six-month follow-up interval, suggesting the potential for sustained weight maintenance efficacy with the procedural intervention.
“The fact that the therapeutic benefit seems to augment over time rather than diminish, and that it exhibits a dose-response relationship akin to pharmacological agents, is particularly heartening,” remarked Dr. Sullivan. “This provides us with a strong degree of confidence in our hypothesis that we are addressing the correct biological mechanisms.”
No significant adverse events were documented in relation to either the device employed or the procedural intervention itself.
“Beyond the recovery from general anesthesia, there is minimal convalescence required,” stated Dr. Sullivan. “Individuals can typically resume their daily activities within approximately 24 hours. Participants were unable to discern whether they had received the active procedure or the sham intervention, as the post-procedural symptomology is generally negligible.”
Dr. Sullivan elaborated that the procedure specifically targets the small intestine, the site where the hormones mimicked by GLP-1 medications are endogenously produced. Prolonged consumption of diets rich in fats and sugars can induce thickening and other alterations in the duodenal mucosal layer. These pathological changes can disrupt proper gut-food signaling pathways, thereby impacting hormonal regulation and contributing to insulin resistance and metabolic disorders. By restoring the integrity of the mucosal layer, the resurfacing procedure aims to re-establish an individual’s metabolic equilibrium at their post-GLP-1 weight, thereby fostering enduring outcomes.
Duodenal mucosal resurfacing is classified as an investigational outpatient procedural therapy. The pivotal REMAIN-1 program, a comprehensive study involving over 300 participants and sponsored by Fractyl Health, has successfully completed enrollment and randomization. Topline data from the six-month pivotal cohort are anticipated in the early part of the fourth quarter of 2026, with a planned submission for marketing approval later in the same year.
